Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 20/20 | 0.74 |
| ▸ | AR | P10275 | 6/20 | 0.74 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.74 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.74 |
| ▸ | ESR1 | P03372 | 1/20 | 0.74 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5883764 | 0.87 | PGR (0.67) | PGRARNR3C1NR3C2ESR1 | |
| SCHEMBL5883207 | 0.85 | PGR (1.00) | PGRARNR3C1NR3C2ESR1 | |
| SCHEMBL5883652 | 0.84 | PGR (0.60) | PGRARNR3C1NR3C2ESR1 | |
| SCHEMBL5358293 | 0.80 | PGR (0.71) | PGRARNR3C1NR3C2 | |
| SCHEMBL5361847 | 0.78 | PGR (0.72) | PGRARNR3C1NR3C2ESR1 | |
| SCHEMBL5361844 | 0.78 | PGR (0.72) | PGRARNR3C1NR3C2ESR1 | |
| SCHEMBL5361838 | 0.78 | PGR (0.72) | PGRARNR3C1NR3C2ESR1 | |
| SCHEMBL5365115 | 0.77 | PGR (0.74) | PGRARNR3C1NR3C2ESR1 | |
| SCHEMBL5365122 | 0.77 | PGR (0.74) | PGRARNR3C1NR3C2ESR1 | |
| SCHEMBL5883806 | 0.77 | PGR (0.69) | PGRARNR3C1NR3C2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060223839-A1 | 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5H-chromeno-[3,4-f]-quinolines as selective progesterone receptor modulator compounds | LIGAND PHARMACEUTICALS, INCORPORATED | 2006-10-05 | — | — | US | claimed |
| US-7084151-B2 | 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5H-chromeno[3,4-ƒ]quinolines as selective progesterone receptor modulator compounds | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2006-08-01 | — | — | US | claimed |
| US-20040147530-A1 | 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5H-chromeno[3,4-f]quinolines as selective progesterone receptor modulator compounds | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2004-07-29 | — | — | US | claimed |
| US-20060223839-A1 | 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5H-chromeno-[3,4-f]-quinolines as selective progesterone receptor modulator compounds | LIGAND PHARMACEUTICALS, INCORPORATED | 2006-10-05 | — | — | US | disclosed |
| US-7084151-B2 | 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5H-chromeno[3,4-ƒ]quinolines as selective progesterone receptor modulator compounds | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2006-08-01 | — | — | US | disclosed |
| US-20040147530-A1 | 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5H-chromeno[3,4-f]quinolines as selective progesterone receptor modulator compounds | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223839-A1 | 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5H-chromeno-[3,4-f]-quinolines as selective progesterone receptor modulator compounds | PGR, GPER1, PGRMC1 | PGR 1/4885AR 24/4885NR3C1 7/4885 |
| US-20040147530-A1 | 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5H-chromeno[3,4-f]quinolines as selective progesterone receptor modulator compounds | PGR, GPER1, PGRMC1 | PGR 1/4885AR 25/4885NR3C1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.